This website uses cookies to help us give you the best experience when you visit our website. By continuing to use this website, you consent to our use of these cookies.

Find out more about how we use cookies and how to manage them by reading our cookie notice.

Ross Stewart

Ross Stewart is part of the Translational Medicine group within MedImmune, and supports translational strategy and execution across a range of immunotherapy programs.
Prior to this he spent 7 years as part of the research group at MedImmune, which is responsible for basic biology, preclinical pharmacology and drug discovery across the oncology portfolio. During this time he helped establish preclinical platforms that support MedImmune immunotherapy programs currently in discovery and development. He led a number of preclinical programs through their discovery phase, including MEDI4736 (anti-PD-L1), played a significant role in the in-licensing of tremelimumab and was a member of the early clinical development teams for both molecules.
Prior to joining MedImmune Ross received a PhD from The University of Birmingham Medical School, where he studied the impact of CD40 signal strength in B-cell activation and survival.

You are viewing: All posts Reset filters

Nothing Found

Apologies, but no results were found for the requested archive. Perhaps searching will help find a related post.

About LabTalk

LabTalk is AstraZeneca’s new science-focused blog.

On LabTalk you can hear from scientists, researchers and academics discussing novel ideas, research and innovation.

Read comment policy

Our Authors

Latest from Twitter

Follow AstraZeneca: